New Drug Carrimycin

Carrimycin is our latest technology and product contribution to global public health and life health. Based on the long-term research results of genetic engineering drugs, our scientists have successfully developed Chinese Class 1.1 innovative drugs with clinical application value using "synthetic biology technology" for the first time in the world. Excellent leading technology has enabled Carrimycin to obtain Chinese national patents and more than 70 patents in more than ten countries, including the United States. This technology and product with completely independent intellectual property rights in China were rated as the Top Ten Progress of Chinese Medical Biotechnology in 2019 by China Medicinal Biotechnology Association and Chinese Medicinal Biotechnology.



Carrimycin showed stability and safety in the clinical treatment of COVID-19 pneumonia in China. According to the comprehensive assessment of the Ministry of Science and Technology of the People's Republic of China, Carrimycin is a safe and effective domestic drug for treating COVID-19 pneumonia and is included in the "Three Drugs and Three Prescriptions" for the treatment of COVID-19 pneumonia in China. On October 9, 2020, Shenyang Tonglian Group successfully submitted an application for phase III clinical study of Carrimycin against COVID-19 pneumonia to the US FDA based on randomized, open, controlled, and multicenter clinical studies in China. After strict evaluation by FDA experts, on November 7, 2020, the US FDA approved the phase III clinical study of Carrimycin against severe COVID-19 pneumonia, which will create more hope for lives.